Serum S100A8/A9 May Act as Biomarker of Atherosclerosis Severity in Psoriasis

Grantham, Henry J.; Hussain, Amaani; Reynolds, Nick J.

doi:10.1016/j.jid.2022.06.018

Cited by 6 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The advantages of register-based studies are long follow-up time, large sample sizes and the ability to investigate actual CV events rather than surrogates. Studies using circulating inflammatory biomarkers in blood as surrogates for subclinical CVD in patients with psoriasis have also been conducted, these biomarkers include, e.g., GlycA [ 54 ], S100A8/9 [ 55 ], growth differentiation factor-15 (GDF-15) [ 56 ], high-sensitivity (hs)-CRP [ 57 ] and the neutrophil-to-lymphocyte ratio (NLR) [ 5 ]. Some of these biomarkers are also known predictors of CVD in the general population [ 58 – 60 ].…”

Section: Discussionmentioning

confidence: 99%

Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies

Kaiser,

Näslund-Koch,

Kvist-Hansen

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease associated with an increased risk of cardiovascular disease (CVD). The risk of CVD increases with the severity of psoriasis, and exposure to systemic inflammation may partly explain the increased risk of CVD in these patients. This raises the question of whether anti-psoriatic treatment, in addition to treating the skin lesions, also lowers the risk of developing CVD. Different types of studies have examined the impact of systemic anti-psoriatic treatments on the risk of CVD in patients with psoriasis and epidemiological observational studies with, e.g., myocardial infarction and stroke as outcomes, and clinical studies investigating circulating inflammatory biomarkers in the blood indicate that anti-psoriatic therapy has a protective effect; however, no randomized controlled trial (RCT) has examined the impact of systemic anti-psoriatic treatment on future hard cardiovascular endpoints. This narrative review provides an overview of the clinical cardiovascular imaging studies examining the effect of systemic anti-psoriatic treatment on the risk of subclinical CVD in patients with psoriasis. We found a total of 24 clinical imaging studies, where 16 of these were observational cohort studies and eight were RCTs. The observational studies suggest an improvement in the risk of subclinical CVD based on different cardiovascular imaging biomarkers; however, the RCTs showed inconsistent results and mainly included vascular inflammation as the outcome. Future RCTs including other imaging biomarkers as surrogates for subclinical CVD, with longer follow-up and with hard cardiovascular endpoints are warranted to address whether systemic anti-psoriatic treatments reduce the risk of CVD.

show abstract

Section: Discussionmentioning

confidence: 99%

Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies

Kaiser,

Näslund-Koch,

Kvist-Hansen

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Ранее на когорте больных с атеросклерозом периферических артерий (n=331, средний возраст 70 лет) было показано, что в АСБ регистрируются высокие уровни кальпротектина, кроме того, высокие уровни кальпротектина в сыворотке ассоциировались с повышенным риском конечных точек (ампутация конечности, смерть по Российский кардиологический журнал 2023; 28 (11) причине ССЗ) в 1,8 раз (p=0,034) [16]. В исследовании 2022г была также выявлена положительная связь между уровнем кальпротектина в сыворотке и наличием АСБ в коронарных артериях у пациентов с псориазом [17]. Данные об ассоциации кальпротектина с повышенным уровнем СРБ широко представлены в исследовании больных с различными ревматическими заболеваниями (анкилозирующий спондилоартрит, ревматоидный артрит), характеризующихся, в свою очередь, высоким риском развития ССЗ [18].…”

Section: Discussionunclassified

Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders

Kolesova,

Usoltsev,

Moguchaia

et al. 2023

Russ J Cardiol

View full text Add to dashboard Cite

Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years.Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out.Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns.Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.

show abstract

“…The potential of S100s as targets for psoriasis diagnosis and treatment has been suggested. Henry J. Grantham et al proposed that S100A8/9 in serum can serve as a biological indicator of atherosclerosis caused by psoriasis [90]. Helia B. Schonthaler et al identified S100A9 as a chromatin component that regulates C3 expression in mouse and human cells by binding to a region upstream of the C3 initiation site.…”

Section: S100 Protein and Psoriasismentioning

confidence: 99%

“…S100A8/A9: Serum S100A8/A9 levels may act as biomarker of atherosclerosis severity in psoriasis; deletion of them enhances inflammation in imiquimod-induced psoriasis mice [88,90].…”

Section: Hmgb1mentioning

confidence: 99%

Damage-Associated Molecular Patterns, a Class of Potential Psoriasis Drug Targets

Gao,

Gong,

Chen

et al. 2024

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic skin disorder that involves both innate and adaptive immune responses in its pathogenesis. Local tissue damage is a hallmark feature of psoriasis and other autoimmune diseases. In psoriasis, damage-associated molecular patterns (DAMPs) released by damaged local tissue act as danger signals and trigger inflammatory responses by recruiting and activating immune cells. They also stimulate the release of pro-inflammatory cytokines and chemokines, which exacerbate the inflammatory response and contribute to disease progression. Recent studies have highlighted the role of DAMPs as key regulators of immune responses involved in the initiation and maintenance of psoriatic inflammation. This review summarizes the current understanding of the immune mechanism of psoriasis, focusing on several important DAMPs and their mechanisms of action. We also discussed the potential of DAMPs as diagnostic and therapeutic targets for psoriasis, offering new insights into the development of more effective treatments for this challenging skin disease.

show abstract

Serum S100A8/A9 May Act as Biomarker of Atherosclerosis Severity in Psoriasis

Cited by 6 publications

References 13 publications

Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies

Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies

Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders

Damage-Associated Molecular Patterns, a Class of Potential Psoriasis Drug Targets

Contact Info

Product

Resources

About